(Q38937691)

English

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

multicenter clinical trial

0 references

0 references

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Silke Gillessen

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Gedske Daugaard

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

D Keizman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

M O Fosboel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

H Reichegger

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

A Peer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

E Rosenbaum

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

M-C Desax

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

V Neiman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

P M Petersen

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

J Mueller

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

R Cathomas

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

M Gottfried

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

H Dresler

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

D Sarid

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

W Mermershtain

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

K Rouvinov

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

A Omlin

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

28 February 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

289-293

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

https://scigraph.springernature.com/pub.10.1038/pcan.2017.6

0 references

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Visceral disease in castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2017.6

21 January 2018

Identifiers

10.1038/PCAN.2017.6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28244493%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38937691&oldid=1504369550"